Knowledge and information are critical tools to affect early diagnosis in pituitary disease. Join Dr. Lewis Blevins and Jorge D Faccinetti cofounders, as they navigate the wonders and complexities of pituitary conditions.
In today’s podcast, Dr. Lewis Blevins dives into the fascinating findings from a study by Corcept Therapeutics on the prevalence of hypercortisolism in people with type 2 diabetes.
This is a very informative discussion about the new indications of the Cushing’s Drug Isturisa® (osilodrostat) with Dr. Mario Maldonado, who heads global development for endocrinology at Recordati Rare Diseases.
I recently had the pleasure of meeting Camurus CEO Fredrik Tiberg. We initially connected on a Zoom call and later met at the European Endocrine Conference held in Copenhagen, Denmark in May. We agreed to meet in person, learn more about the company and record a podcast.
In today’s podcast, Dr. Lewis Blevins discusses relacorilant, a drug currently in development by Corcept Therapeutics for the treatment of hypercortisolism. Clinical trials to date have shown encouraging results, with improvements in blood pressure, glucose control, weight, and body composition.
Sometimes conversations take interesting turns and often lead to surprising and unexpected discussions. If you’re a regular listener of the Pituitary Podcast, you may have caught a few of our live broadcasts where these unscripted discussion are common.Today I’m joined by Risa August, a patient and advocate and a frequent guest sharing her work, adventures and advocacy efforts, for one of those engaging chats.
